Allergy Therapeutics plc (LON:AGY - Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as GBX 9 ($0.12) and last traded at GBX 8.50 ($0.11), with a volume of 127774 shares changing hands. The stock had previously closed at GBX 8.50 ($0.11).
Allergy Therapeutics Stock Performance
The firm has a market cap of £357.48 million, a PE ratio of -1,041.67, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a quick ratio of 1.48, a current ratio of 1.63 and a debt-to-equity ratio of 835.48. The firm has a 50-day moving average price of GBX 8.22 and a two-hundred day moving average price of GBX 7.20.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
